Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

mruyog 304 posts  |  Last Activity: Mar 27, 2015 5:51 PM Member since: Mar 3, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Do Not Forget That

    by mruyog Feb 9, 2015 3:12 PM
    mruyog mruyog Feb 10, 2015 11:00 AM Flag

    No CEO in his right mind works for traders, he is working for investing shareholders!! He doesn't even bother to read posts on the Yahoo board because the boards on Yahoo are infested badly with traders and vermin who are in the stocks to make their daily living and not investing in the company with faith in the well being of the company!! Traders do not care whether a company does well or not, all they care is how to make a few pennies a day trading to make their living!! So, how can you expect Scarlett make you happy?!!

  • mruyog mruyog Feb 10, 2015 10:49 AM Flag

    The meaning of the word "theory" in science has been slaughtered in media and by many half-educated writers. It's so widespread that I am afraid the dictionaries will start defining the word "theory" as not much different than the word "hypothesis"!! You are right, Jack; but, posters on this board do not have enough background in science and I find a lot of semi-pandits posing like pandits. I have learned to read ALL posts on this board just for fun and not for any deeper understanding. For the latter, you have to find your own resources. Go to the right resources to find some authentic information, not on this board. And, please do not waster your time by frequent posts on this board - it's useless.

  • Reply to

    The Sldes Show

    by mruyog Feb 9, 2015 12:19 PM
    mruyog mruyog Feb 9, 2015 4:38 PM Flag

    You neither want to lie nor to exaggerate to these CEOs because they can easily figure out if you do so!! If there is no news worthy of reporting or it's premature to do so, why should he do it? Share price will always be manipulated in current-day markets and CEOs of such companies usually ignore sentiment of traders and hedgies!! They can't do their business right if they keep fighting the market sentiment. Just understand that. Look at only the facts and logic I stated before on this post. Thanks for responding.

  • mruyog mruyog Feb 9, 2015 3:19 PM Flag

    Maine, you comment sarcastically on posts from all. But, let me tell you: Throuh this post of yours, you exhibit nothing but your sheer ignorance and lack of intelligence to judge that this presentation was to CEOs and not to WS guys or in a hematologic conference!! Judge it from that fact instead of looking for diamond in a vegetable market!!

  • the presentation was to CEO's, not Wall Street guys or in a hematology conference!! It was designed to be informative to an audience most of which did not have any idea what Geron is and where it is now; nothing else. I have been at pains to tell you guys this for some time and was not expecting any breakthgrough announcement important to CEOs, beacuse that announcement (specifically, the J&J deal) is out already!! This is to build up awareness of a smart-group of people who were otherwise ignorant about the company and where it stands now. If you review the presentation wih that in mind, you will understand the value of it!!

  • Reply to

    The Sldes Show

    by mruyog Feb 9, 2015 12:19 PM
    mruyog mruyog Feb 9, 2015 3:02 PM Flag

    demeter, do not forget that this presentation was to CEOs, not Wall Street guys!! The presentation was perfect for the audience most of who did not have any idea what Ocata stands for and where it is!! If you view the presentation with that in mind, Wotton did do a good job. You do not want to stuff such a presentation with fake optimism and exaggeration. CEOs are not a dunb-class specie!! He did it just right.

  • Reply to

    The Sldes Show

    by mruyog Feb 9, 2015 12:19 PM
    mruyog mruyog Feb 9, 2015 2:47 PM Flag

    Guys, the company doesn't have enough money but possesses substantial intellectual wealth worth billions of dollars!! The actual worth of a clinical-stage biotech is NOT counted on the basis of just cash in hand, it's primarily its intellectual wealth. Anybody disagreeing with this is unqualified to judge the worth of Ocata.

  • Reply to

    The Sldes Show

    by mruyog Feb 9, 2015 12:19 PM
    mruyog mruyog Feb 9, 2015 2:35 PM Flag

    Keep, the company had a very bad situation in the past and all those litigations are behind now. It takes time for any new breakthrough treatment to go past the FDA licensing. The company is on marginal financial ground currently but, on the technical ground, it has formidable achievements. Thanks to Lanza'a dedication. But, this is the general situation of many biotechs which are on the similar level. Given all that, the current management is doing right things. You apparently have a leftover bitter taste in your mouth w.r.t. this compnay, and rightfully so: but, you can't dwell only on the past to see a different furure for which you must weigh properly what is the situation now. And, that's: No debt, no litigation, gloring Ph 1 successes in the SMD and AMD trials, platelet success, pretty good chances of FTD grant by the FDA to both SMD and AMD trials, and management focus now fully on how to proceed to successful Ph 2 trials. Yes, all that needs money and, for that, platelet-program partnership (yielding some cash) and the NASDAQ listing, followed by perhaps a needed and meaningful offering. Two more years or less from now and you will see where this company is actually headed. I am optimistic now (not so just a year back!!)

  • Reply to

    BK on the way soon

    by blakes176 Feb 9, 2015 1:44 PM
    mruyog mruyog Feb 9, 2015 2:12 PM Flag

    He is perpetually so!!!

  • Reply to

    The Sldes Show

    by mruyog Feb 9, 2015 12:19 PM
    mruyog mruyog Feb 9, 2015 12:49 PM Flag

    Yes, it has been a frustration to see some meaningful posts on this board - it has been full of vermin's postst!! Thanks.

  • Reply to

    The Sldes Show

    by mruyog Feb 9, 2015 12:19 PM
    mruyog mruyog Feb 9, 2015 12:44 PM Flag

    The partnership deal I referenced above is for platelets, and not for the SMD or AMD trials. No partnership deal at this time and going alone for the SMD/AMD trials thus is a very smart idea because once the FTD is granted or the results are very encouraging, much more lucrative partnership deals can be nailed down then, easily covering dilution effect, if any. I think the company is in the right direction and on to a glorious future. Looking at the potential market for a "first in kind" treatment for the SMD and AMD, holders of Ocata shares thus must be very well rewarded within just a few years.

  • Reply to

    The Sldes Show

    by mruyog Feb 9, 2015 12:19 PM
    mruyog mruyog Feb 9, 2015 12:32 PM Flag

    If this works out well, along with a partnership deal before year-end 2015, the company may not need to raise thre float as much since the NASDAQ listing this quarter and the trial results available may jack up the share price by early 2016 to a level that may require the issuance of added shares to minimal quantity. Then, you may be better off accumulating now since, dilution if any, will be neutralized by the rise in the SP. Those afraid of dilution may then be regretful if they do not see this.

  • Reply to

    The Sldes Show

    by mruyog Feb 9, 2015 12:19 PM
    mruyog mruyog Feb 9, 2015 12:21 PM Flag

    Oops, read "Slides" instead of "Sldes" above!!

  • RPE cells show mature effect within 6 months to a year after injecting, meaning SMD Ph 2 results should have clearer effectiveness demonstrated by end of third quarter 2015 if the trial starts soon: and, 2nd quarter 2016 for AMD if that trial starts a quarter later. Hopefully, the FDA may grant the fast track to the SMD trial in early 2016 and to the AMD trial in late 2016 or even earlier if Ocata management can analyze results well and fast and is quick in sending its request for the FTD to the FDA. Any comments? Only serious ones, please!!

  • Reply to

    I Wonder Who Controls Posting On This Board?

    by mruyog Feb 9, 2015 11:31 AM
    mruyog mruyog Feb 9, 2015 11:34 AM Flag

    Or try being critical of MXXM and your posts are filtered!! There sure seems to be some WS dogs' hand on this board as to what gets posted!!

  • I do not think it's just software. Any time you use the word CXXHXXIXXNXXNXXA or being critical of it, your posts are watched and erased despite not using any other restricted word!! Try!!!

  • Reply to

    Johnsons

    by hayflicklim Feb 5, 2015 10:25 PM
    mruyog mruyog Feb 6, 2015 12:43 PM Flag

    I do not deny manipulation. Of course, it's rampant. What I disagree is that J&J is doing it!! I suspect very much ML and the MM both of who may have been tied with hedge funds. They do this to keep their business going in stock that has very little risk. Monkey traders who are in the business of making their living without sweating just follow the lead.

  • Reply to

    Johnsons

    by hayflicklim Feb 5, 2015 10:25 PM
    mruyog mruyog Feb 6, 2015 10:46 AM Flag

    I get two down-thumbs from idiots who do not have any real clue as to how the system works!!

  • Reply to

    Johnsons

    by hayflicklim Feb 5, 2015 10:25 PM
    mruyog mruyog Feb 6, 2015 10:44 AM Flag

    Look beaver, J&J is not stupid to assume that the other large pharmas are unaware of what this drug IMET is and what its potential multi applications are. If you and I can guess that, they are a lot smarter and knowledgeable than us! These pharmas know what the real value of Geron can be and, believe me, they DO NOT look at the current SP for that because it is always a traders-manipulated value, especially for a clinical-stage biotech like Geron. Therefore, J&J is not a fool to keep the SP low through illegal manipulation (which they may consider too risky for their reputation). It knows that a bidding war for acquisition of Geron when it ensues will have no effect whatsoever of what the current SP is. By involving Janssen in the IMET development and enough share holding through related fund(s), it has already got its foothold and influence with the Geron board to have any need of this stupid idea of controlling the SP. Please do not get the issue off-track which, originally, addressed how Johnsons have got control gf the company, not of its share trading. That latter is a wild guess at best.

  • no one, repeat, no one (including myself, of course!) on this board has any real clue as to why the SP has been low and what really is cooking up at Geron. Lots of wild thoughts (some manipulative) and partial facts (of which many are outdated) have been posted on this board. I have found invariably that these are either misleading or off-track and inaccurate. I do not know what is the opinion of other visitors of this board but I think it is wise to visit this board and post just for fun, without getting personal and serious about getting direction from here. Some posters do provide some useful information; but, not enough to make a confident decision.

GERN
3.85+0.12(+3.22%)Mar 27 4:00 PMEDT